沃爾核材(002130.SZ):授權啟動分拆上海科特至北交所上市的前期籌備工作
格隆匯12月13日丨沃爾核材(002130.SZ)公佈,公司於2021年12月10日召開第六屆董事會第二十六次會議,審議通過了《關於授權公司管理層啟動分拆子公司境內上市前期籌備工作的議案》。根據公司總體戰略佈局,為進一步聚焦主業,結合公司控股子公司上海科特新材料股份有限公司(“上海科特”)業務發展現狀,公司董事會授權公司管理層啟動分拆上海科特至北京證券交易所上市的前期籌備工作。
上海科特是一家專業從事熱敏半導體元器件、電線電纜用硅橡膠和聚烯烴改性材料、新能源電池用硅橡膠材料及製品等特種材料研發、設計、生產、銷售為一體的國家級高新技術企業、國家級專精特新“小巨人”企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.